Pharmexa A/S
🇩🇰Denmark
Clinical Trials
12
Active:10
Completed:1
Trial Phases
2 Phases
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (50.0%)Phase 3
1 (50.0%)A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma.
Phase 2
Completed
- Conditions
- Carcinoma, Hepatocellular
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2008-12-18
- Lead Sponsor
- Pharmexa A/S
- Target Recruit Count
- 41
- Registration Number
- NCT00444782
- Locations
- 🇫🇷
Michel Beaugrand, Bondy, France
🇩🇪Tim F. Greten, Hannover, Germany
🇪🇸Jordi Bruix, Barcelona, Spain
GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer
Phase 3
Terminated
- Conditions
- Advanced Unresectable Pancreatic Cancer
- Interventions
- Biological: GV1001
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2008-05-19
- Lead Sponsor
- Pharmexa A/S
- Target Recruit Count
- 360
- Registration Number
- NCT00358566
- Locations
- 🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸Scripps Clinic Torrey Pines, La Jolla, California, United States
News
No news found